Bristol Myers drops after Reuters reports no ongoing AstraZeneca deal talks
BMY•Reuters says no AstraZeneca-Bristol Myers deal talks are ongoing
- Shares of Bristol Myers Squibb BMY.N fell 2.2% to $64.46 in premarket trading.
- There are "no discussions" ongoing between AstraZeneca AZN.L and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters.
- "There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies," said the source.
- Reuters had earlier reported that initial discussions had taken place, but it was unclear whether talks were still ongoing.
- UK-listed shares of AstraZeneca AZN.L rose 4.5% to £122.58 ($165.13).
- As of the last close, BMY was up 22.2% year to date.
($1 = 0.7419 pounds)
